Posted by Michael Wonder on 27 May 2017
Piramal Imaging and IsoLogic Innovative Radiopharmaceuticals announce commercial approval of Neuraceq by Health Canada
28 February 2017 - Piramal Imaging and IsoLogic Innovative Radiopharmaceuticals today announce that Health Canada has issued a Notice of Compliance to Isologic Innovative Radiopharmaceuticals for NeuraCeq (florbetaben F18 injection).
Isologic has received marketing authorization from Health Canada for the commercial production and market supply of NeuraCeq in Canada.
NeuraCeq is the first diagnostic radiotracer to support the early diagnosis of Alzheimer’s disease that is commercially available in the country. NeuraCeq availability in Canada was previously limited to investigational medicine purposes.
